Background of Approval Optison is an ultrasound imaging contrast agent that received EMA approval on May 17, 1998, authorizing its use throughout Europe.

Clinical Evidence Clinical trials demonstrated prolonged contrast persistence and a low incidence of adverse events.

Market Position Optison competes with existing contrast agents, and its perflutren‑based microbubbles enhance image quality.

Reimbursement and Entry Barriers Variations in national reimbursement policies and the need to secure equipment compatibility across European countries may constitute initial entry barriers.

Future Outlook The product is expected to sustain a revenue base over the long term, and expansion of approved indications could increase market share.